Correlation Between Summit Therapeutics and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both Summit Therapeutics and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Summit Therapeutics and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Summit Therapeutics PLC and Immix Biopharma, you can compare the effects of market volatilities on Summit Therapeutics and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Summit Therapeutics with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Summit Therapeutics and Immix Biopharma.

Diversification Opportunities for Summit Therapeutics and Immix Biopharma

-0.52

Correlation Coefficient

Summit Therapeutics  Immix Biopharma

Excellent diversification

The 3 months correlation between Summit and Immix is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding Summit Therapeutics PLC and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Summit Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Summit Therapeutics PLC are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Summit Therapeutics i.e., Summit Therapeutics and Immix Biopharma go up and down completely randomly.

Pair Corralation between Summit Therapeutics and Immix Biopharma

Given the investment horizon of 90 days Summit Therapeutics PLC is expected to under-perform the Immix Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Summit Therapeutics PLC is 1.56 times less risky than Immix Biopharma. The stock trades about -0.01 of its potential returns per unit of risk. The Immix Biopharma is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  156.00  in Immix Biopharma on September 27, 2024 and sell it today you would earn a total of  62.00  from holding Immix Biopharma or generate 39.74% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Summit Therapeutics PLC  vs.  Immix Biopharma

Summit Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Summit Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Immix Biopharma

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Summit Therapeutics and Immix Biopharma

The main advantage of trading using opposite Summit Therapeutics and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Summit Therapeutics position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind Summit Therapeutics PLC and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.